Evaluating Telitacicept for treating Systemic Lupus Erythematosus
Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE) in the Real World: a Multicenter Retrospective Study
This study is testing if a new treatment called Telitacicept can help people with Systemic Lupus Erythematosus manage their symptoms and improve their health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 139 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06458972 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the safety and efficacy of Telitacicept in patients diagnosed with Systemic Lupus Erythematosus (SLE). It aims to assess how well this dual-target therapy can manage the symptoms and underlying immune dysfunction associated with SLE. Participants will be monitored for their adherence to the treatment and the overall effectiveness of Telitacicept in improving their condition. The study will include patients aged 18 to 70 who meet specific diagnostic criteria for SLE.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 70 diagnosed with Systemic Lupus Erythematosus according to established criteria.
Not a fit: Patients with other rheumatic diseases, active infections, or those using other biologics may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the management of Systemic Lupus Erythematosus, leading to better patient outcomes.
How similar studies have performed: While this approach is based on established mechanisms in SLE treatment, the specific use of Telitacicept in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years old, not exceeding 70 years old (including 70 years old); 2. Patients diagnosed with systemic lupus erythematosus (SLE) according to 2019 American College of Rheumatology/European League Against Rheumatism (2019ACR/EULAR) international classification diagnostic criteria; 3. Accepting the treatment of telitacicept. Exclusion Criteria: Subjects who meet any of the following criteria should be excluded from this study: 1. Patients with other rheumatic immune system diseases; 2. Patients in the active stage of acute and chronic infections; 3. Patients using other biologics; 4. Patients with wasting diseases such as malignant tumors
Where this trial is running
Wuhan, Hubei
- Tongji Hospital — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Dong Lingli, MD — Tongji Hospital
- Study coordinator: Dong Lingli, MD
- Email: tjhdongll@163.com
- Phone: 17742804229
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.